Emisphere Technologies Inc. said today new study results show an oral form of vitamin B12 that the company is developing reduced the amount of time it took for the body to absorb the nutrient, while increasing the amount of the nutrient that was absorbed.
Developing an effective oral form of the nutrient may save millions of Americans from painful injections, needed to ensure they get adequate levels of vitamin B12.
The study, which involved 20 men divided into four groups, showed vitamin B12 absorption was 10 times higher in those given a supplement using Emisphereâ€™s eligen technology, according to the Cedar Knolls, N.J.-based company, which employs 60 workers in research and development at the Landmark at Eastview office complex.
Eligen, which the company has been developing in some form for years, essentially chaperons the nutrient through the digestive system, where it would otherwise be destroyed, into the bloodstream.
Data from the study hold â€œreal promise for improving the way we approach vitamin B12 supplementation,â€ said Donald W. Jacobsen, professor of molecular medicine at Case Western Reserve University in Cleveland.
At least 5 million people a year in the United States receive some 40 million B-12 injections to treat a range of debilitating diseases.
Shares of the company at midday were up by nearly 7 percent to $3.29 a share.